Skip to main content
SpringerLink
Log in

Circulating Tumor Markers

  • Chapter
Principles of Molecular Oncology

  • 1237 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. 1. Anker P, Mulcahy H, Chen XQ, Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Reg. 1999;18:65–73.

    Article  CAS  Google Scholar 

  2. 2. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001;61:1659–1665.

    PubMed  CAS  Google Scholar 

  3. 3. Chang HW, Lee SM, Goodman SN, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Instit. 2002;94:1697–1703.

    CAS  Google Scholar 

  4. 4. Fujimoto A, O'Day SJ, Taback B, Elashoff D, Hoon DS. Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome. Cancer Res. 2004;64:4085–4088.

    Article  PubMed  CAS  Google Scholar 

  5. 5. Umetani N, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006;24:4270–4276.

    Article  PubMed  CAS  Google Scholar 

  6. 6. Simpkins F, Czechowicz JA, Liotta L, Kohn EC. SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics. Pharmacogenomics. 2005;6:647–653.

    Article  PubMed  CAS  Google Scholar 

  7. 7. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;16:572–577.

    Article  Google Scholar 

  8. 8. Baggerly K, Morris J, Coombes K. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics. 2004;20:777–785.

    Article  PubMed  CAS  Google Scholar 

  9. 9. Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005;65:10613–10622.

    Article  PubMed  CAS  Google Scholar 

  10. 10. Ward DG, Cheng Y, N'Kontchou G, et al. Preclinical and post-treatment changes in the HCC-associated serum proteome. Br J Cancer. 2006;95:1379–1383.

    Article  PubMed  CAS  Google Scholar 

  11. 11. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 2006;66:5540-5541.

    Article  PubMed  CAS  Google Scholar 

  12. 12. Cook A, Huddart R, Jay G, Norman A, Dearnaley D, Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br J Cancer. 2000;82:1952–1957.

    Article  PubMed  CAS  Google Scholar 

  13. 13. Johansen J, Rasmussen AA, Overgaard M, Valentin-Hansen P. Conserved Small Non-coding RNAs that belong to the sigma(E) Regulon: Role in Down-regulation of Outer Membrane Proteins. J Mol Biol. 2006;364:1–8.

    Article  PubMed  CAS  Google Scholar 

  14. 14. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106 (5):1130–1139.

    Article  PubMed  CAS  Google Scholar 

  15. 15. Cabrespine A, Guy L, Gachon F, Cure H, Chollet P, Bay JO. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. J Urol. 2006;175:1347–1352.

    Article  PubMed  CAS  Google Scholar 

  16. 16. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006; 12:447–453.

    Article  PubMed  CAS  Google Scholar 

  17. 17. Holten-Andersen MN, Nielsen HJ, Sorensen S, Jensen V, Brunner N, Christensen IJ. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer. Eur J Cancer. 2006;42:1889–1896.

    Article  PubMed  CAS  Google Scholar 

  18. 18. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103:512–517.

    Article  PubMed  CAS  Google Scholar 

  19. 19. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442–446.

    Article  PubMed  CAS  Google Scholar 

  20. 20. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002;2:750–763.

    Article  PubMed  CAS  Google Scholar 

  21. 21. Brawer MK. How to use prostate-specific antigen in the early detection or screening for prostatic carcinoma. CA A Cancer Journal for Physicians. 1995;45:148–164.

    Article  CAS  Google Scholar 

  22. 22. Perlin E, Engeler J, Edson M, Karp D, McIntire KR, Waldman TA. The value of serial measurement of both HCG and AFP for monitoring germ cell tumours. Cancer. 1976;37:215–219.

    Article  PubMed  CAS  Google Scholar 

  23. 23. Norgaard-Pedersen B, Albrechtsen R, Bagshawe KD, et al. Clinical use of AFP and HCT in testicular tumours of germ cell origin. Lancet. 1978;ii:1042.

    Article  Google Scholar 

  24. 24. Thompson DK, Haddow JE. Serial monitoring of serum alpha-fetoprotein and chorionic gonadotrophin in males with germ cell tumours. Cancer. 1979;43:1820–1829.

    Article  PubMed  CAS  Google Scholar 

  25. 25. Mead GM, Stenning SP, Cook P, et al. International germ cell consensus classification: a prognostic factor- based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603.

    Google Scholar 

  26. 26. von Eyben F. Laboratory markers and germ cell tumors. Crit Rev Clin Lab Sci. 2003;40:377–427.

    Article  Google Scholar 

  27. 27. Tucker DF, Oliver RTD, Travers P, Bodmer WF. Serum marker potential of placental alkaline phosphatase-like activity in germ cell tumours evaluated by H17E2 monoclonal antibody assay. Br J Cancer. 1985;51:631–639.

    Article  PubMed  CAS  Google Scholar 

  28. 28. Horwich A, Tucker DF, Peckham MJ. Placental alkaline phosphatase as a tumour marker in seminoma using the H17 E2 monoclonal antibody assay. Br-J-Cancer. 1985;51:625–629.

    Article  PubMed  CAS  Google Scholar 

  29. 29. Lajer H, Daugaard G, Andersson AM, Skakkebaek NE. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer. Int J Cancer. 2002;100:244–246.

    Article  PubMed  CAS  Google Scholar 

  30. 30. Tatarinov Y. Detection of embryonspecific alpha globulin in the blood sera of patients with primary liver tumour. Vopr Med Khim. 1964;10:90–91.

    PubMed  CAS  Google Scholar 

  31. 31. Kohn J, Weaver P. Serum-alpha-fetoprotein in hepatocellular carcinoma. Lancet. 1974;ii:334–337.impossible

    Article  Google Scholar 

  32. 32. Waldman JA, McIntire K. The use of a radioimmunoassay for alphafetoprotein in the diagnosis of malignancy. Lancet. 1974;34:1510–1515.

    Google Scholar 

  33. 33. Horwich A, Huddart R, Dearnaley D. Markers and management of germ-cell tumours of the testes. The Lancet. 1998;352:1535–1538.

    Article  CAS  Google Scholar 

  34. 34. Hartmann J, Nichols C, Droz J-P, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002;13:1017–1028.

    Article  PubMed  CAS  Google Scholar 

  35. 35. Hoff Wanderas E, Fossa SD, Tretli S. Risk of a second germ cell cancer after treatment of a primary germ cell cancer in 2201 Norwegian male patients. European Journal of Cancer. 1997;33:244–252.

    Article  Google Scholar 

  36. 36. Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ. Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol. 1994;12:120–126.

    PubMed  CAS  Google Scholar 

  37. 37. Horwich A, Peckham MJ. Serum tumour marker regression rate following chemotherapy for malignant teratoma. Eur J Cancer Clin Oncol. 1984;20:1463–1470.

    Article  PubMed  CAS  Google Scholar 

  38. 38. Speeg KJ, Azizkhan JKS. The stimulation by methotrexate of human chorionic gonadotrophin and placental alkaline phosphatase in cultured choriocarcinoma cells. Cancer Res. 1976;36: 4570–4576.

    PubMed  CAS  Google Scholar 

  39. 39. Browne P, Bagshawe KD. Enhancement of human chorionic gonadotrophin production by antimetabolites. Br J Cancer. 1982;46:22–29.

    Article  PubMed  CAS  Google Scholar 

  40. 40. de Wit R, Sylvester R, Tsitsa C, et al. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer. Br J Cancer. 1997;75:432–435.

    Article  PubMed  Google Scholar 

  41. 41. Murphy BA, Motzer RJ, Mazumdar M, et al. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosphamide salvage chemotherapy. Cancer. 1994;73:2520–2526.

    Article  PubMed  CAS  Google Scholar 

  42. 42. Fizazi K, Culine S, Kramar A, et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol. 2004;22:3868–3876.

    Article  PubMed  Google Scholar 

  43. 43. Andreyev HJN, Dearnaley DP, Horwich A. Testicular non-seminoma with high serum human chorionic gonadotrophin: The trophoblastic teratoma syndrome. Diagn Oncol. 1993;3:67–71.

    Google Scholar 

  44. 44. Christensen TB, Engbaek F, Marqversen J, Nielsen SI, Kamby C, von der Maase H. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer. 1999;80:1577–1581.

    Article  PubMed  CAS  Google Scholar 

  45. 45. Chybowski FM, Bergstralh EJ, Oesterling JE. The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol. 1992;148:83–86.

    PubMed  CAS  Google Scholar 

  46. 46. Ercole CJ, Lange PH, Mathisen M, Chiou RK, Reddy PK, Vessella RL. Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J Urol. 1987;138:1881–1884.

    Google Scholar 

  47. 47. Oesterling JE, Chan DW, Epstein JI, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localised prostatic cancer treated with radical prostatectomy. J Urol. 1988;139:766–772.

    PubMed  CAS  Google Scholar 

  48. 48. Brawer MK, Chetner M, Beatie J, Buchner DM, Vessella RL, Lange PH. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;137:841–845.

    Google Scholar 

  49. 49. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161.

    Article  PubMed  CAS  Google Scholar 

  50. 50. Cooner WH, Mosley BR, Rutherford CJ, Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146–1154.

    PubMed  CAS  Google Scholar 

  51. 51. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol. 1992;147:846–851.

    PubMed  CAS  Google Scholar 

  52. 52. Stamey TA, Kabalin JN, Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol. 1989;141:1088–1090.

    PubMed  CAS  Google Scholar 

  53. 53. Partin AW, Carter HB, Chan DW, et al. Prostate specific antigen in the staging of localised prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol. 1990;143:747–752.

    PubMed  CAS  Google Scholar 

  54. 54. Chybowski FM, Keller JJL, Bergstralh EJ, et al. Predicting radionuclide bone scan findings in patients with newly diagnosed untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991;145:313–318.

    PubMed  CAS  Google Scholar 

  55. 55. Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum prostate specific antigen determination before and after radical prostatectomy. J Urol. 1989;141:873–879.

    PubMed  CAS  Google Scholar 

  56. 56. Lightner DJ, Lange PH, Reddy PK, Moore L. Prostate specific antigen and local recurrence after radical prostatectomy. J Urol. 1990;1441:921–926.

    Google Scholar 

  57. 57. Meek AG, Park TL, Oberman E, Wielopolski L. A prospective study of prostate specific antigen levels in patients receiving radiotherapy for localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1990;19:733–741.

    Article  PubMed  CAS  Google Scholar 

  58. 58. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol. 1992;10:1208–1217.

    PubMed  CAS  Google Scholar 

  59. 59. Miller PD, Eardley I, Kirby RS. Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer. Br J Urol. 1992;70:295–298.

    PubMed  CAS  Google Scholar 

  60. 60. Kelly W, Scher H, Mazumdar M, Vlamis V, Schwartz M, Fossa S. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993;11:607–615.

    PubMed  CAS  Google Scholar 

  61. 61. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitroxantrone plus prednisone or prednisone along for symptomatic hormone-resistant prostate cancer: A Canadian randomised trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.

    PubMed  CAS  Google Scholar 

  62. 62. Small EJ, McMillan A, Meyer M, et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001;19:1304–1311.

    PubMed  CAS  Google Scholar 

  63. 63. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516–521.

    Article  PubMed  Google Scholar 

  64. 64. Parker C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 2004;5: 101–106.

    Article  PubMed  Google Scholar 

  65. 65. Eastham JA. Prostate-specific antigen doubling time as a prognostic marker in prostate cancer. Nat Clin Pract Urol. 2005;2: 482–491.

    Article  PubMed  CAS  Google Scholar 

  66. 66. Semeniuk RC, Venner PM, North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology. 2006;68:565–569.

    Article  PubMed  Google Scholar 

  67. 67. Primrose JN, Bleiberg H, Daniel F, et al. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. Br J Cancer. 1999;79:867–872.

    Article  CAS  Google Scholar 

  68. 68. Park YJ, Park KJ, Park JG et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg. 1999;23:721–726.

    Article  PubMed  CAS  Google Scholar 

  69. 69. Mala T, Bohler G, Mathisen O, et al: Hepatic resection for colorectal metastases: Can preoperative scoring predict patient outcome? World J. Surg. 2002;26:1348–1353.

    Article  PubMed  Google Scholar 

  70. 70. Aabo K, Pedersen H, Kjaer M. Carcinoembryonic antigen (CEA) and alkaline phosphastase in progressive colorectal cancer with special reference to patient survival. Eur J Cancer Clin Oncol. 1986;22:211–213.

    Article  PubMed  CAS  Google Scholar 

  71. 71. Staab HJ, Anderer FA, Brummendorf T, Stumpf E, Fischer R. Prognostic value of preoperative serum CEA level compared to clinical staging. Br J Cancer. 1981;44:652–654.

    Article  PubMed  CAS  Google Scholar 

  72. 72. Wanebo JH, Rao B, Pinskey C. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978;299:448–450.

    Article  PubMed  CAS  Google Scholar 

  73. 73. Lewi H, Blumgart LH, Carter DC. Preoperative carcinoembryonic antigen and survival in patients with colorectal cancer. Br J Surg. 1984;71:206–208.

    Article  PubMed  CAS  Google Scholar 

  74. 74. Goslin R, Steele G, MacIntyre J. The use of preoperative plasma CEA levels for the stratification of patients after curative resection of colorectal cancer. Ann Surg. 1980;192:747–749.

    Article  PubMed  CAS  Google Scholar 

  75. 75. Webb A, Scott-Mackie P, Cunningham D. The prognostic value of CEA, beta HCG, AFP, CA 125, CA 19-9 and C-erb B- 2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995;6:581–587.

    PubMed  CAS  Google Scholar 

  76. 76. Chau I, Allen MJ, Cunningham D, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol. 2004;22:1420–1429

    Article  PubMed  CAS  Google Scholar 

  77. 77. Weiss NS, Cook LS. Evaluating the efficacy of screening for recurrence of cancer. J Natl Inst Cancer. 1998;90:1870–1872.

    Article  CAS  Google Scholar 

  78. 78. Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and non specific gastrointestinal symptoms. J Gastrointest Surg. 1997;1:106–112.

    Article  PubMed  CAS  Google Scholar 

  79. 79. Okusaka T, Okada S, Sato T. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer. Hepatogastroenterol 1998;45:867–872.

    CAS  Google Scholar 

  80. 80. Rocha Lima CM, Savarese D, Bruckner H, et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 2002;20:1182–1191.

    Article  PubMed  Google Scholar 

  81. 81. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 Update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–5327

    Article  PubMed  CAS  Google Scholar 

  82. 82. Jacobs I, Davies AP, Bridges J. Prevalence screening for ovarian cancer in postmenopausal women by CA 124 measurement and ultrasonography. Br Med J. 1993;306:1030–1034.

    Article  CAS  Google Scholar 

  83. 83. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obst Gynaecol. 1990;97:922–9229.

    Article  CAS  Google Scholar 

  84. 84. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000;82:1535–1538.

    Article  PubMed  CAS  Google Scholar 

  85. 85. Rustin GJ, Timmers P, Nelstrop A, et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol. 2006;24:45–51.

    Article  PubMed  CAS  Google Scholar 

  86. 86. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynaecol Oncol. 1992;44:1030–1034.

    Article  Google Scholar 

  87. 87. Duffy MJ, Duggan C, Keane R, et al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem. 2004;50:559–563.

    Article  PubMed  CAS  Google Scholar 

  88. 88. Buffaz PD, Gauchez AS, Caravel JP. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nuclear Med. 1999;26:8–11.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was undertaken in The Royal Marsden NHS Foundation Trust who received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive. This work was supported by the Institute of Cancer Research, the Bob Champion Cancer Trust and Cancer Research UK Section of Radiotherapy [CUK] grant number C46/A2131.

Author information

Authors and Affiliations

  1. The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK

    Alan Horwich & Gill Ross

Authors
  1. Alan Horwich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gill Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Hospital General of Granollers, Barcelona, Spain

    Miguel H. Bronchud MD, PhD

  2. MA Foote Associates, Westlake Village, CA, USA

    Mary Ann Foote PhD

  3. National Cancer Institute, Bethesda, Maryland

    Giuseppe Giaccone MD, PhD

  4. University of Chicago Medical Center, Chicago, IL, USA

    Olufunmilayo Olopade MD

  5. CRC Center for Cancer Therapeutics, Surrey, UK

    Paul Workman PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc.

About this chapter

Cite this chapter

Horwich, A., Ross, G. (2008). Circulating Tumor Markers. In: Bronchud, M.H., Foote, M.A., Giaccone, G., Olopade, O., Workman, P. (eds) Principles of Molecular Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-470-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-470-4_5

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-25-1

  • Online ISBN: 978-1-59745-470-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation